{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:10:51Z","timestamp":1791727851674,"version":"4.3.4"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T00:00:00Z","timestamp":1331251200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0033379","type":"journal-article","created":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T19:53:12Z","timestamp":1331322792000},"page":"e33379","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":53,"title":["Activation of PI3K\/AKT and MAPK Pathway through a PDGFR\u03b2-Dependent Feedback Loop Is Involved in Rapamycin Resistance in Hepatocellular Carcinoma"],"prefix":"10.1371","volume":"7","author":[{"given":"Quan-Lin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ming","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Jun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Wu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,3,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global Cancer Statistics.","volume":"61","author":"A Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2005.07.019","article-title":"How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?","volume":"43","author":"M Schwartz","year":"2005","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.","volume":"8","author":"M Guba","year":"2002","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2008.03.024","article-title":"Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.","volume":"49","author":"AC Piguet","year":"2008","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-07-4774","article-title":"Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.","volume":"14","author":"Z Wang","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.","volume":"248","author":"M Vivarelli","year":"2008","journal-title":"Ann Surg"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/TP.0b013e3181c3c540","article-title":"Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.","volume":"89","author":"M Vivarelli","year":"2010","journal-title":"Transplantation"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.23437","article-title":"Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.","volume":"51","author":"C Toso","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1054\/drup.2002.0227","article-title":"Mechanisms of resistance to rapamycins.","volume":"4","author":"S Huang","year":"2001","journal-title":"Drug Resist Updat"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.bjc.6603353","article-title":"Predicted mechanisms of resistance to mTOR inhibitors.","volume":"95","author":"RT Kurmasheva","year":"2006","journal-title":"Br J Cancer"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"e7373","DOI":"10.1371\/journal.pone.0007373","article-title":"Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines.","volume":"4","author":"RH Jimenez","year":"2009","journal-title":"PLoS One"},{"issue":"34","key":"ref12","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.3748\/wjg.v17.i34.3922","article-title":"Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.","volume":"17","author":"FM Gu","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI200317222","article-title":"Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.","volume":"112","author":"H Zhang","year":"2003","journal-title":"J Clin Invest"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1172\/JCI28984","article-title":"PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR.","volume":"117","author":"H Zhang","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1083\/jcb.200408161","article-title":"Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.","volume":"167","author":"BD Manning","year":"2004","journal-title":"J Cell Biol"},{"issue":"9","key":"ref16","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.","volume":"118","author":"A Carracedo","year":"2008","journal-title":"J Clin Invest"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1074\/jbc.M110.183087","article-title":"mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.","volume":"286","author":"J Liu","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases.","volume":"103","author":"J Schlessinger","year":"2000","journal-title":"Cell"},{"issue":"23","key":"ref19","first-page":"2912","article-title":"Oncogenic derivatives of platelet-derived growth factor receptors.","volume":"61","author":"AV Jones","year":"2004","journal-title":"Cell Mol Life Sci"},{"issue":"Pt 8","key":"ref20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1242\/jcs.114.8.1533","article-title":"Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor.","volume":"114","author":"H Izumi","year":"2001","journal-title":"J Cell Sci"},{"issue":"42","key":"ref21","doi-asserted-by":"crossref","first-page":"39769","DOI":"10.1074\/jbc.M204483200","article-title":"p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y.","volume":"277","author":"A Hackzell","year":"2002","journal-title":"J Biol Chem"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1015701232589","article-title":"Sp1 is a key regulator of the PDGF beta-receptor transcription.","volume":"28","author":"C Molander","year":"2001","journal-title":"Mol Biol Rep"},{"issue":"18","key":"ref23","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","article-title":"Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies.","volume":"14","author":"OJ Shah","year":"2004","journal-title":"Curr Biol"},{"issue":"24","key":"ref24","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.4161\/cc.7.24.7244","article-title":"Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.","volume":"7","author":"A Carracedo","year":"2008","journal-title":"Cell Cycle"},{"issue":"19","key":"ref25","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activation and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.","volume":"64","author":"SM Wilhelm","year":"2004","journal-title":"Cancer Res"},{"issue":"8B","key":"ref26","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/j.1582-4934.2009.00692.x","article-title":"Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.","volume":"13","author":"H Huynh","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-10-0666","article-title":"Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.","volume":"10","author":"AC Piguet","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"ref28","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3748\/wjg.v12.i19.3114","article-title":"Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.","volume":"12","author":"J Zhou","year":"2006","journal-title":"World J Gastroentero"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.transproceed.2008.03.165","article-title":"Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.","volume":"40","author":"J Zhou","year":"2008","journal-title":"Transplant Proc"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2010.01.025","article-title":"Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.","volume":"52","author":"S Bhoori","year":"2010","journal-title":"J Hepatol"},{"issue":"43","key":"ref31","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.3748\/wjg.v16.i43.5518","article-title":"Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.","volume":"16","author":"Y Wang","year":"2010","journal-title":"World J Gastroenterol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0033379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,2]],"date-time":"2022-01-02T10:30:16Z","timestamp":1641119416000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0033379"}},"subtitle":[],"editor":[{"given":"Xin-yuan","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,3,9]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0033379","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,9]]}}}